Nwam LLC bought a new stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 5,698 shares of the pharmaceutical company’s stock, valued at approximately $231,000.

A number of other institutional investors have also added to or reduced their stakes in GSK. Geode Capital Management LLC lifted its position in GlaxoSmithKline PLC by 46.3% during the 1st quarter. Geode Capital Management LLC now owns 129,145 shares of the pharmaceutical company’s stock valued at $5,444,000 after purchasing an additional 40,858 shares during the period. Paloma Partners Management Co lifted its position in GlaxoSmithKline PLC by 31.3% during the 1st quarter. Paloma Partners Management Co now owns 13,002 shares of the pharmaceutical company’s stock valued at $549,000 after purchasing an additional 3,102 shares during the period. HighTower Advisors LLC lifted its position in GlaxoSmithKline PLC by 12.5% during the 1st quarter. HighTower Advisors LLC now owns 512,417 shares of the pharmaceutical company’s stock valued at $21,588,000 after purchasing an additional 56,739 shares during the period. Macquarie Group Ltd. lifted its position in GlaxoSmithKline PLC by 5.0% during the 1st quarter. Macquarie Group Ltd. now owns 2,539,877 shares of the pharmaceutical company’s stock valued at $107,081,000 after purchasing an additional 119,899 shares during the period. Finally, Oak Associates Ltd. OH lifted its position in GlaxoSmithKline PLC by 59.5% during the 1st quarter. Oak Associates Ltd. OH now owns 283,080 shares of the pharmaceutical company’s stock valued at $11,935,000 after purchasing an additional 105,580 shares during the period. Institutional investors own 9.29% of the company’s stock.

WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/nwam-llc-buys-shares-of-5698-glaxosmithkline-plc-gsk/1685576.html.

Shares of GlaxoSmithKline PLC (GSK) traded down $0.29 during mid-day trading on Tuesday, reaching $35.85. 609,316 shares of the company’s stock traded hands, compared to its average volume of 5,470,000. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The firm has a market cap of $86,790.00, a P/E ratio of 12.82, a P/E/G ratio of 2.00 and a beta of 1.00. GlaxoSmithKline PLC has a 52-week low of $35.78 and a 52-week high of $44.53.

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a yield of 5.62%. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 158.40%.

A number of research analysts have issued reports on the stock. Investec downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Monday. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Bank of America Corporation downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, October 24th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company’s stock. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and a consensus target price of $44.33.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.